Optimized expression of HPV 31 L1 in yeast

Details for Australian Patent Application No. 2004224335 (hide)

Owner Merck Sharp & Dohme Corp.

Inventors Schultz, Loren D.; Jansen, Kathrin U.; Markus, Henry Z.; Neeper, Michael P.

Agent Spruson & Ferguson

Pub. Number AU-B-2004224335

PCT Pub. Number WO2004/084831

Priority 60/457,172 24.03.03 US

Filing date 19 March 2004

Wipo publication date 7 October 2004

Acceptance publication date 28 January 2010

International Classifications

C12P 21/06 (2006.01) Preparation of peptides or proteins - produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

C07K 14/025 (2006.01) Peptides having more than 20 amino acids

C12N 15/33 (2006.01) Mutation or genetic engineering - Genes encoding viral proteins

Event Publications

6 October 2005 PCT application entered the National Phase

  PCT publication WO2004/084831 Priority application(s): WO2004/084831

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

28 January 2010 Application Accepted

  Published as AU-B-2004224335

27 May 2010 Standard Patent Sealed

11 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004224338-Expandable spherical spinal implant

2004224332-Esterified fatty acid composition